Connect with us

General News

Possibility of Brain Disorders in COVID-19 Patients

mm

Published

on

Recent researches revealed that people with mild COVID-19 symptoms have a chance of developing fatal brain disorders.

COVID-19 is an infection that differently attacks every individual. Some people develop acute respiratory problems while others only develop mild symptoms like fever, cough etc. Mostly, doctors tend to ignore the patients with mild symptoms as they get normal on their own. However, the recent reports revealed some shocking and disturbing detail about the virus.

Brain Disorders in COVID-19 Patients

Coronavirus can trigger brain disorders in patients. Scientists have warned that doctors may be overlooking signs of brain disorders in patients with mild coronavirus symptoms. Neurologists in U.K. found over 40 coronavirus patients with severe brain inflammation, nerve damage, delirium and even a stroke. This is a serious condition called acute disseminated encephalomyelitis (Adem). Cases of Adem have risen from one case a month to 2-3 weekly cases in the months of April and May.

Also Read: Cannabis Maybe A Cure For Various Cancers

Doctors are particularly worried because no virus has previously affected the brain as COVID-19 is. A 55-year-old COVID-19 patient without any history of mental illness, started behaving oddly the day after getting discharged from the medical center. She was having recurrent hallucinations. Another 47 year-old woman was admitted with a headache. However, later, she became unresponsive. The doctors conducted an emergency surgery to cut out a portion of her skull to release pressure on her inflammed brain.

Also Read: Human Trials for Coronavirus Vaccines Have Started in The U.K.

 

The way COVID-19 affects the brain hasn’t been observed before with any other virus. This could very well be due to the fact that the virus has numerous mutations. However, that is just speculation for now.

So, what needs to be done?

Well, clinicians need to be on their toes about these complications of the coronavirus. Patients with memory issues, fatigue, weakness, numbness, or cognitive symptoms need special attention. Healthcare workers, GPs, and physicians should also consult neurologists in regard to these cases.

Note that these are all precautions. It does not neglect the fact that complete recovery isn’t possible. In most cases, the coronavirus does not involve the brain.

Because of the intensity of the symptoms of the virus most of the patients in hospitals cannot be examined through brain scanners or other procedures. Therefore, the full spectrum of brain disorders caused by the corona virus cannot be determined just yet. Efficient research needs to be done to determine the complete depth of the complications.

One major concern!

One major concern with this new discovery is the possibility of the virus to leave the affected people with brain disorders that could only become apparent later in life. The number of such cases might not be as staggering, but that is still a major concern.

This has happened before in flu outbreak in 1918. After the pandemic, almost a million patients came up with brain disorders.

It is far too early to give a verdict, but it could still haunt the people like a ghost. Like most subtle brain disorders, the effects might not become apparent at once. However, in the years to come it could affect the lifestyles of a lot of people.

One should hope that it doesn’t come to that. But, with a pandemic affecting people by thousands everyday, being alert is the wisest thing to do.

 

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Cannabis

What Does 2020 Hold For Marijuana Stocks?

mm

Published

on

marijuana stocks

The relaxation of marijuana-related laws across the USA has certainly increased investment prospects in marijuana stocks. With rising global interest in the market, the future of marijuana stocks holds promising results for investors.

This move has opened new opportunities for the venture portfolios of stakeholders in the market.  If things move in the right direction, one can expect exceptional returns along with improvements in economic indicators.

Is 2020 a year of recession?

The year 2020 has seen unbridled economic uncertainty and changing trends in the stock market so far. After a slight recovery from the market crash that began in February, speculations of further bearish market trends have left investors, skeptical.

For some stakeholders, classifying this year as a period of recession is an early ruling. The National Bureau of Economic Research, however, has a contradicting verdict. It categorizes 2020 as a recessive year due to the unconventional drop in unemployment and production it triggered globally.

It is not surprising to see how the stock market is striving hard to recover from the recent unexpected blows. Investment opportunities offered by marijuana stocks can certainly help economies tolerate the effects of this partial recession. Many hope this year sees a shorter dip of growth as compared to the previous episodes of contraction.

CNBC

Did marijuana stocks perform well in 2020?

Despite the pandemic, the trend in the growth of marijuana stocks has been encouraging in the past few months. This trend has made marijuana stocks a safe haven for investors who are hungry for higher returns on investments.

Part of this growth in marijuana stocks can be associated with the pandemic itself. People following SOPS are turning towards marijuana usage for recreational purposes, causing a spike in consumption.

The recent policy by 11 states permitting recreational marijuana usage is a big move that has spiked marijuana stock prices. In addition, 33 other states that permitted medicinal usage, has opened new windows for marijuana-related investments.

This decriminalization of marijuana has also become a new and attractive source of tax revenue for the government. According to Forbes, the state of Washington has generated around $319 million in cannabis tax revenue, while California and Colorado produced $ 300 million and $266 million respectively.

With the increasing burden of social benefits, these tax revenues may spike federal interest. This factor has also piqued the interest of stakeholders, as the marijuana industry has not only survived well but outperformed various sectors in this pandemic permeated year, making it a big source for job generation and tax revenues for the government.

This has been a much welcome change for ancillary companies like KushCo holdings Inc. The company has seen a massive growth of 130% since March of 2020, as compared to the previous losses of 45% in revenues. The company now stands on the hot list for investors, who are eyeing it as a profitable future investment.

Other companies like OrganiGram Holdings, Aurora Cannabis, Aphria, etc. are also making it to that list successfully. This can be associated with increased demands from countries like Poland, Germany, and Canada, which now allow recreational marijuana use.

Another less discussed factor that may probe spikes in marijuana stock prices is an increased diversion of the general public towards alternate medicine. There are speculations for the CBD market to grow to $1.3 billion by 2022 from a $390 million in 2018 according to New Frontier Data.

With big chain stores like Kroger, Wholefoods, and American Eagle showing interest in selling an extended range of CBD products, investors can expect the market for marijuana and its related derivatives to see a positive trend in growth rate, providing profitable investment prospective.

All in all, it can be deduced that the marijuana industry has a lot of potentials not only in the United States but also globally. This makes it a safe investment for stakeholders considering the market trends so far.

Continue Reading

General News

Study: Cannabis Terpene Treatment For COVID-19

Published

on

Cannabis Terpene NT-VRL

A recent Israeli study has found a possible treatment for COVID-19 complications in cannabis. The chemical CBD (cannabidiol) has been studied in a combination with a cannabis terpene (NT-VRL). This CBD is one of the key ingredients in cannabis sativa. Meanwhile, the cannabis terpene NT-VRL (patent of Ebyna) is an aromatic chemical from the flowers of the plant. When administered in combination, there has been a noticeable positive effect on ‘cytokine storm’, a feared complication of COVID-19.

Cytokine storm is a dangerous reaction to COVID-19 by the body’s immune system

The term ‘cytokine storm’ refers to a chain reaction of immune cells, causing increasing levels of inflammation. Because the body is responding the the coronavirus infecting the patient, it secretes small proteins called ‘cytokines’. Usually, these have small but important roles in helping kill off the virus by creating inflammation and fever. However, when this reaction goes unchecked, it can be deadly if untreated. The patient would undergo very high levels of fever, fatigue, inflammation and in worst-cases, respiratory failure.

This is why the recent discovery that COVID-19 can lead to cytokine storm was so shocking. It meant that even young, healthy people with strong immune systems would be susceptible to potential deaths from this disease. Furthermore, the most widely-used drug of choice for treating this, dexamethasone, is undergoing global shortage.

The company, Ebyna, had patented the cannabis terpene, NT-VRL

The study was a collaboration between Ebyna, the terpene company, and Cannasoul, a cannabis research entity. Thus, Ebyna and Cannasoul’s joint venture led to the formation of an inhalant drug. This contained NT-VRL, to be administered with or without CBD. The aim of the study was to investigate the effects they had on treating cytokine storm from COVID-19.

Long just dismissed as simply useful in the flavor/smell of cannabis products, terpenes were shown to be very effective in this case. When combined with the CBD, which has also been shown to have positive health effects, it was remarkable. The combined therapy of both CBD and NT-VRL significantly improved symptoms of cytokine storm from COVID-19.

“This type of delivery [inhaled, rather than ingested] method is a game-changer enabling us to achieve therapeutic qualities from these unique phytochemicals like never before,” said Nadav Eya, the CEO of Ebyna. He was referring to the unexpected efficacy of the NT-VRL therapy in this COVID-19 complication.

Other studies confirm Ebyna-Cannasoul’s findings

Outside of Israel, several studies report similar findings. More and more researchers are turning to cannabis byproducts to battle the COVID-19 pandemic.

Igor and Olga Kovalchuck, researchers from Canada, were both developing a new strain of cannabis. Their aim was to extract anti-cancer drugs from it. However, the new COVID-19 pandemic caused them to shift focus towards combating the coronavirus. Their strain is hoped to be able to produce a drug that could reduce the communicability of SARS-CoV2. It would do so by restricting the ACE-2 receptors in the body.

All in all, Ebyna and Cannasoul’s NT-VRL terpene may just be revolutionary. The existence of terpene as an anti-cytokine storm drug is still debatable, and more research is still required. However, their study and that of corroborators have shown that cannabis is even more useful a plant than we had ever suspected. For more news and updates on the state of the CBD-terpene therapy, stay tuned. In the meanwhile, check out other recent studies on CBD here.

Continue Reading

General News

Endocanna Health Aims To Increase Genetic Risk Awareness For COVID-19

Published

on

COVID-19

This pandemic is practically unprecedented in terms of how mysterious its risk factors are. While the mode of transmission is known, the exact factors that make a person susceptible to severe complications aren’t. Experts all agree that COVID-19 may either pass the infected with no symptoms, cause mild respiratory effects or in worst-cases deaths.

However, what still remains unclear is who is vulnerable and why. That’s why Endocanna Health, a cannabinoid DNA-research company based in California, has stepped up. They are offering a free DNA test for genetic factors in their consumers. This test is meant to scan for known genetic markers that could lead to susceptibility. While the gesture is generous, it must be cautioned such a test is not meant to be a reliable tool to assess this.

DNA research works by looking for known markers

The aim of Endocanna Health’s test is to examine possible vulnerable genes. Such genes could make a person’s immune system weaker to infection, or allow them to develop worse symptoms.

However, if you’re wondering why you haven’t been prescribed this test before, there’s a reason. Most healthcare providers and experts don’t rely on such tests because they only indicate correlation. There is no way to prove the causation. What that means, simply, is that certain genes can make COVID-19 more severe, not always. Factors like age, diet, health conditions and mental health are important too, though.

Endocanna Health’s research is most notable for its work on the human endocannabinoid system. This system includes the way certain cannabinoid neurotransmitters work to regulate mood, sensation, memory, metabolism and immunity.

The system was discovered by scientists investigating the effects of THC in marijuana on the body. While we did just mention immunity back there, it must be kept in mind that this is only part of it (more on that later).

The company’s Chief Science Officer, Dr Chris Spooner, recently claimed that the work they were doing would be useful for understanding the immune system. He mentioned the presence of cannabinoid receptors in the immune cells, that affected the strength of immune response to COVID-19. While the role of cannabinoids on the cells is clear, the message behind the aims should be scrutinized.

Your genes are not the most important factor in beating COVID-19

If Endocanna Health’s aim is to combat COVID-19, then that’s commendable. But if they think that it will significantly contribute to flattening the curve, their hopes are a tad misplaced. Major health experts, from Dr Anthony Fauci to the WHO, all assert that the number one rule to follow is to stay healthy and socially distance. If you’re worried about COVID-19, or another similar disease, then eat healthy, sleep well and stay home. DNA tests can be helpful, truly, in the case of congenital disease (think cystic fibrosis or hemophilia). But to cause misinformation about them is deliberately harmful. Let’s look at the real unsung heroes in the body’s immune system.

To fight infection, circulating white blood cells (called leucocytes) detect and attack germs. They also signal the release of chemicals like prostaglandins to create inflammation and fever, which can be beneficial.

Other cells, like mast cells, help signal the response to rest of the system. Then, from the antigens of the germs, ‘B-Cells’ create antibodies. Antibodies are basically drugs to kill off any other germs left, from bacteria to coronaviruses. This whole process is wonderfully self-regulated. And knowing your genes will just make you more paranoid than actually help, it seems.

Continue Reading

Trending

error: Content is protected !!